RCS - ReNeuron Group plc - Jefferies 2019 Global Healthcare Conference
RNS Number : 7207AReNeuron Group plc31 May 2019
31 May 2019
AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Jefferies 2019 Global Healthcare Conference
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that the Company's management team will be participating in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday 4 June 2019 in New York City.
For further information on the conference, please visit the following link: Jefferies 2019 Global Healthcare Conference
ENDS
Contacts:
ReNeuron
+44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor Relations)
+44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US Media/Investor Relations)
Claudia Styslinger, David Rosen
+1 212 600 1902 or email
claudia@argotpartners.com
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison
+44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, Mark Taylor
+44 (0) 20 7496 3000
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDNRACKDDPPBKKNPN
Recent news on ReNeuron
See all newsREG - ReNeuron Group plc - Directorate Change
AnnouncementREG - FTSE Russell - ReNeuron Group
AnnouncementREG - ReNeuron Group plc - Appointment of Administrators
AnnouncementREG - ReNeuron Group plc - Intention to Appoint Administrators
AnnouncementREG - ReNeuron Group plc - Block Listing Review & Total Voting Rights
Announcement